Peptide statistics 2026: the peptide drug market, FDA approvals and compounded peptide use

peptide drugs have reached the market since the introduction of insulin almost a century ago¹

Uses include diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain.

non-insulin peptide drugs had been approved worldwide since 2000, as of a 2022 review²

peptides were in active clinical development, with many more in preclinical studies²

As of the 2022 review.

in worldwide peptide drug sales in 2019²

The review describes this as more than a two-fold increase compared with 2013.

in 2025 worldwide revenue for Mounjaro (tirzepatide), up 99% from $11,540 million in 2024³

in 2025 revenue for Zepbound (tirzepatide for obesity), up 175% from $4,926 million in 2024³

in 2025 sales of Ozempic (semaglutide), up 6% in Danish kroner and 10% at constant exchange rates⁴

in 2025 sales of Wegovy (semaglutide for obesity), up 36% in Danish kroner and 41% at constant exchange rates⁴

in Novo Nordisk obesity care sales in 2025, up from DKK 6 billion in 2019⁴

TIDES (peptide and oligonucleotide drugs) were approved by the FDA in 2023⁵

Including the first core-symptom treatment for Rett syndrome, which is peptide-based.

novel drugs were approved by the FDA in 2024, including four TIDES (two peptides and two oligonucleotides)⁶

novel drugs were approved by the FDA in 2025, including elamipretide, the first disease-specific treatment for Barth syndrome⁷

FDA approved the first oral GLP-1 for obesity, once-daily oral semaglutide 25 mg (Wegovy pill)⁴

total weekly prescriptions for the Wegovy pill as of January 23, 2026, after its January 5, 2026 launch⁴

Novo Nordisk says uptake was mainly driven by the 1.5 mg starter dose in the self-pay channel.

of US adults said they were currently using a GLP-1 drug⁸

KFF Health Tracking Poll fielded October 27 to November 2, 2025.

of US adults said they had ever used a GLP-1 drug⁸

of adults aged 50 to 64 said they were currently using a GLP-1 drug, the highest of any age group⁸

Versus 11% of those 30 to 49, 9% of those 65 and older and 4% of those 18 to 29.

of adults who had ever used a GLP-1 drug got it from an online provider or website⁸

76% got it from a primary care doctor or specialist and 9% from a medical spa or aesthetic medical center.

of GLP-1 users said the drugs were difficult to afford⁸

14% of past users said they stopped because of cost.

FDA determined the semaglutide shortage was resolved⁹

Enforcement discretion for 503B outsourcing facilities ran until May 22, 2025; the 503A period has also ended.

FDA reaffirmed that the tirzepatide shortage, first declared resolved on October 2, 2024, was over⁹

Enforcement discretion for 503B outsourcing facilities ran until March 19, 2025.

adverse event reports associated with compounded semaglutide had been received by FDA as of May 31, 2026¹⁰

FDA notes some dosing-error events required hospitalization.

adverse event reports associated with compounded tirzepatide had been received by FDA as of May 31, 2026¹⁰

FDA added several peptides, including GHRP-2, GHRP-6, ipamorelin and kisspeptin-10, to category 2 (substances that may present significant safety risks)¹¹

Category 2 is part of FDA's interim policy for bulk substances nominated for compounding.

bulk drug substances remain in FDA's category 2 list of substances that may present significant safety risks¹¹

Count of entries listed on the page, content current as of April 22, 2026.

substances, including BPC-157, TB-500, CJC-1295, Melanotan II and MOTs-C, are listed by FDA as previously in category 2 but withdrawn by their nominators¹¹

FDA still lists its safety concerns, such as immunogenicity risk, for each. Leaving category 2 does not add a substance to the 503A bulks list, which requires rulemaking.

peptides (BPC-157, KPV, TB-500, MOTs-C, emideltide, Semax and epitalon) were scheduled for FDA Pharmacy Compounding Advisory Committee review on July 23 and 24, 2026¹²

FDA evaluated BPC-157 for ulcerative colitis, TB-500 for wound healing and MOTs-C for obesity and osteoporosis.

advisory committee vote, with 1 abstention, to recommend BPC-157, KPV and TB-500 for the 503A bulks list¹³

News report. MOTs-C passed 7-5 with 2 abstentions, emideltide was voted down and FDA staff had recommended against all seven. The votes are nonbinding and rulemaking would be required.

clinical study was found among 36 studies of BPC-157 included in a 2025 systematic review; the other 35 were preclinical¹⁴

The review found no clinical safety data. In the one clinical study, 7 of 12 patients reported knee pain relief for more than 6 months.